Abstract: An object of the present invention is to provide an oxaliplatin-encapsulating liposome aqueous dispersion that has excellent long-term storage stability. The present invention provides an aqueous dispersion of liposomes encapsulating oxaliplatin, the oxaliplatin-encapsulating liposome aqueous dispersion containing 2-morpholinoethanesulfonic acid in an external aqueous phase.

Abstract: An object of the present invention is to provide an oxaliplatin-encapsulating liposome aqueous dispersion that has excellent long-term storage stability. The present invention provides an aqueous dispersion of liposomes encapsulating oxaliplatin, the oxaliplatin-encapsulating liposome aqueous dispersion containing 2-morpholinoethanesulfonic acid in an external aqueous phase.

Abstract: Provided are nanofunctional silica particles having excellent functionality and quality, and capable of being mass-produced at low costs. According to the present invention, there are provided nanofunctional silica particles including a coating layer containing one or more silica compounds selected from the group consisting of mercaptopropyl trimethoxysilane (MPS), mercaptopropyl triethoxysilane (MPES), mercaptopropyl methyldimethoxysilane (MPDMS), trimethoxy[2-(7-oxabicyclo[4.1.0]-hept-3-yl)ethyl]silane (EpoPS), thiocyanatopropyl triethoxysilane (TCPS), acryloxypropyl trimethoxysilane (ACPS), and aminopropyl trimethoxysilane (APS); and functional particles in the coating layer, and being used in imaging, assay, diagnosis, treatment or the like, medicine or bioresearch.

Abstract: Colloidal silica particles containing a fluorescent dye compound, composed of a silica particle containing a silica component and a fluorescent dye compound chemically bound or adsorbed thereto, wherein the colloidal silica particles containing a fluorescent dye compound have an average diameter of 30 nm or less, and wherein said silica particles are used simultaneously as fluorescent-labelling nanobeads; a fluorescent nano-material comprising said colloidal silica particles; and a biochip and an assay method using the same.

Abstract: The present invention provides a method for providing information and an apparatus for providing information with which information can be secretly displayed, and further, a display technique with a lot of sense of fun can attract keen interest from people around a display such as digital signage. A method for providing information using an apparatus for providing information that displays information using a light array includes: switching and displaying an information array and a concealment array in a display cycle in which a person cannot sense an information display array of the information array using the apparatus for providing information. The information array includes the information display array concerning information to be provided, and the concealment array is generated so that the information display array becomes invisible when the concealment array overlaps with the information array.

Abstract: The purpose of the present invention is to provide a therapeutic agent or preventive agent for exacerbation of influenza, specifically to provide a novel pyruvate dehydrogenase kinase 4 (PDK4) inhibitor. The present invention relates to a PDK4 inhibitor, medical composition or cosmetic composition containing as the active ingredient a compound represented by any one of the following general formulas (I) through (III) and a pharmaceutically acceptable ester derivative thereof, or a pharmaceutically acceptable salt of the same.

Abstract: The invention provides a radiation intensity measuring apparatus for each of small sealed radiation sources for cancer therapy that is capable of measuring multiple cartridges. The apparatus includes a device for setting up multiple cartridges and a device for measuring the radiation intensities of radiation passing through a narrow slit. Radiation is emitted from multiple radiation sources and the radiation measurement device moves simultaneously together with the slit along with the side of cartridge holding device while scanning the radiation intensities. Included is a radiation detection scanning device for measuring radiation intensities for each of the radiation sources passing through the narrow slit, and a slit shielding system for restricting radiation originated originating from both the side neighboring radiation sources.

Abstract: The carotid artery plaque properties are quantitatively determined by a carotid artery echo whereby predicting incidence of cerebral infarction or myocardial infarct. A method includes obtaining, coloring, and displaying steps. In the obtaining step, the integrated amounts per unit time of echo signals corresponding to pixels of an echo image of carotid artery plaque are obtained. The signals are obtained when the image is obtained by an IBS method. In the coloring step, the relationship between ranges and colors is referenced. The available full range of the integrated amount is previously divided into the ranges. The colors are assigned to the ranges. The pixels are classified into the ranges in accordance with the integrated amounts corresponding to the pixels. The pixels of the image are colored in colors corresponding to the ranges of the pixels. In the displaying step, the colored echo image is displayed on a display portion 30.

Abstract: Provided is a radiation intensity measuring apparatus for each of small sealed radiation sources for cancer therapy capable of measuring multiple cartridges efficiently and rapidly.

Abstract: An object of the present invention is to provide an oxaliplatin-encapsulating liposome aqueous dispersion that has excellent long-term storage stability. The present invention provides an aqueous dispersion of liposomes encapsulating oxaliplatin, the oxaliplatin-encapsulating liposome aqueous dispersion containing 2-morpholinoethanesulfonic acid in an external aqueous phase.

Abstract: A system for evaluating activation of the pathway mediated by ATF6. More specifically, a method for screening an endoplasmic reticulum stressor, as well as a method for screening a substance for suppressing an endoplasmic reticulum stress induced by the activation of the pathway mediated by ATF6, and a method for screening an antidiabetic drug candidate. A method for real-time evaluation of activation of the pathway mediated by ATF6 in viable cells. The method uses a polynucleotide encoding a nonfluorescent peptide domain derived from a fluorescent protein and an ATF6 protein domain.

Abstract: Provided is a prophylactic/therapeutic agent for influenza viral infection that is effective not only before and at an early stage of infection with influenza virus but also at an intermediate or late stage of the infection and is highly safe for human bodies. A prophylactic/therapeutic drug for influenza viral infection comprising, as active ingredients, 5-aminolevulinic acid (5-ALA), a derivative thereof or a salt of the 5-ALA or the derivative, and an iron compound is prepared. This prophylactic/therapeutic agent can be used for ameliorating (preventing) depression in food consumption, water consumption and body weight, for ameliorating (decreasing) increase in ketone body levels in blood that may otherwise cause ketosis, for ameliorating (preventing) depression in ATP levels in blood, or for ameliorating (increasing) a survival rate and depression in a body surface temperature.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with ?-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.

Abstract: An object of the present invention is to further enhance the antitumor effect when oxaliplatin is administered in combination with a combination drug containing tegafur, gimeracil and oteracil potassium. According to the present invention, by using oxaliplatin encapsulated in a liposome preparation, combination therapy of oxaliplatin plus a combination drug containing tegafur, gimeracil and oteracil potassium, is revealed to show remarkably enhanced antitumor effect without increasing side effects.

Abstract: The present invention provides a method for detecting ACF by analyzing a test region of large intestine tissue at the molecular level. Namely, the present invention relates to a method for detecting aberrant crypt foci (ACF) that comprises detecting an ACF detection marker in a test region of large intestine tissue, by using one or more types of molecules for which ACF-specific expression increases as the ACF detection marker, the molecule being selected from the group consisting of SLC2a1, and SLC7a7; an ACF detection marker for detecting the ACF in human-derived large intestine tissue, that is SLC2a1, or SLC7a7; and, a method for evaluating risk of colorectal cancer and colorectal adenoma in subjects based on the results of detecting ACF in a test region of large intestine tissue of the subjects using the aforementioned ACF detection method.

Abstract: Provided is alloy for medical use and a medical device that is novel and useful. The alloy for medical use according to, for example, an embodiment of the present invention is mainly composed of three kinds of elements of gold (Au), platinum (Pt), and niobium (Nb). A total content of the three kinds of elements can be no smaller than 99% by weight, in which a platinum content can be no smaller than 5% by weight and no greater than 50% by weight and a niobium content can be no smaller than 3% by weight and no greater than 15% by weight. By adjusting the content ratio of the three elements, for example, it is possible to reduce or prevent artifacts in an MRI. Non-magnetization is also possible.

Abstract: A system of quantitatively determining a biomolecule, which has: allowing fluorescent silica particles capable of emitting fluorescence detectable by a flow cytometer to capture a target biomolecule fluorescent-labelled for quantitative determination; detecting the fluorescence emitted from the fluorescent silica particles themselves by using the flow cytometer; and measuring the intensity of the fluorescence of the labelled target biomolecule, thereby quantitatively determining the target biomolecule.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with ?-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.

Abstract: Provided is a novel cancer-treating agent which can be used as a novel choice for the treatment of cancer. Specifically provided are: a peptide that inhibits binding of ERAP1 polypeptide to PHB2 polypeptide, which comprises a binding site of the ERAP1 polypeptide to the PHB2 polypeptide, and a pharmaceutical composition comprising the peptide. In addition, provided is a method for screening a drug candidate for treating and/or preventing cancer using inhibition of the binding of the ERAP1 polypeptide to PP1? polypeptide, PKA polypeptide or PKB polypeptide as an index.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with ?-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.